• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • AI Medical Devices and SaMDs: Classification Guidelines Released

AI Medical Devices and SaMDs: Classification Guidelines Released

Monday, 26 July 2021 / Published in Medical Device, News, NMPA Registration in China

AI Medical Devices and SaMDs: Classification Guidelines Released

On July 8, 2021, the China NMPA (National Medical Products Administration) announced (No. 47, 2021) the classification guidelines for artificial intelligence medical devices and SaMDs (Software as Medical Devices). This regulatory announcement covers standardized definitions of product attributes and applicable categories that can provide technical guidance to the medical device industry and regulatory authorities for product registration and registration renewal.

Highlights

At present, the AI software products in the medical field are mainly intended for data processing, decision support, etc., hence, the key factors for determining the product classification includes the intended use of the product and the algorithm maturity level.

According to the announcement, the definitions of Class II and Class III SaMDs are provided below:

Class III SaMDs

  • Used to assist in decision-making, such as the provision of lesion characteristics identification, lesion nature determination, medication guidance, treatment plan development and other clinical treatment recommendations

Class II SaMDs

  • Used for non-aided decision-making, such as data processing and measurement to provide clinical reference information, etc.

*Both classifications use algorithms with low maturity which means they are not previously listed in the market or the product safety and effectiveness is not yet proven.

This release continues NMPA’s close focus on SaMD including AI and machine learning products (see here for previous news).

By Colleen Xu and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Artificial Intelligence medical devices, SaMD

What you can read next

Regulatory Updates for Implant Products in September 2021
China – Updates for voluntary product safety certification (instead CCC)
Certificate of Clearance for all Food Imports

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.